100 related articles for article (PubMed ID: 7804689)
1. Single dose OKT3: adverse effects, pharmacokinetics, and anti-OKT3 antibody response.
Madden RL; Schroeder TJ; Alexander JW; First MR
Transplant Sci; 1994 Sep; 4(1):111-4. PubMed ID: 7804689
[No Abstract] [Full Text] [Related]
2. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
3. OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
Cinti P; Cocciolo P; Evangelista B; Orlandini AM; Bruzzone P; Renna Molajoni E; Cortesini R
Transplant Proc; 1996 Dec; 28(6):3214-6. PubMed ID: 8962245
[No Abstract] [Full Text] [Related]
4. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
[No Abstract] [Full Text] [Related]
5. OKT3 antibody response study: comparative testing of human antimouse antibody.
Kimball JA; Norman DJ; Shield CF; Schroeder TJ; Lisi P; Garovoy M; O'Connell JB; Stuart F; McDiarmid SV; Wall W
Transplant Proc; 1993 Apr; 25(2 Suppl 1):74-6. PubMed ID: 8465432
[No Abstract] [Full Text] [Related]
6. Low-dose OKT3 for cadaveric renal transplantation.
Schweizer RT; Roper L; Hull D; Bartus SA
Transplant Proc; 1992 Dec; 24(6):2592-3. PubMed ID: 1465875
[No Abstract] [Full Text] [Related]
7. Cytomegalovirus infection during OKT3 treatment for renal allograft rejection.
Morgan JD; Horsburgh T; Simpson A; Donnelly PK; Veitch PS; Bell PR
Transplant Proc; 1992 Dec; 24(6):2634-5. PubMed ID: 1334589
[No Abstract] [Full Text] [Related]
8. Detection of anti-idiotypic antibodies after OKT3 treatment by flow cytometry.
Hesse CJ; Jutte NH
Transplantation; 1996 Jan; 61(1):169. PubMed ID: 8560562
[No Abstract] [Full Text] [Related]
9. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
10. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
11. Murine monoclonal CD3 antibody (OKT3)-based early rejection prophylaxis in pediatric heart transplantation.
Shaddy RE; Bullock EA; Morwessel NJ; Hannon DW; Renlund DG; Karwande SV; McGough EC; Hawkins JA
J Heart Lung Transplant; 1993; 12(3):434-9. PubMed ID: 8329414
[TBL] [Abstract][Full Text] [Related]
12. Reduction of the initial febrile response to OKT3 with indomethacin.
First MR; Schroeder TJ; Hariharan S; Weiskittel P
Transplant Proc; 1993 Apr; 25(2 Suppl 1):52-4. PubMed ID: 8465426
[No Abstract] [Full Text] [Related]
13. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B
Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
[TBL] [Abstract][Full Text] [Related]
14. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.
Colvin RB; Preffer FI
Clin Lab Med; 1991 Sep; 11(3):693-714. PubMed ID: 1934971
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of OKT3 therapy: increased risk with impaired renal function.
Kehinde EO; Scriven SD; Feehally J; Veitch PS; Varty K; Bell PR
Transplant Proc; 1994 Aug; 26(4):1945-7. PubMed ID: 8066629
[No Abstract] [Full Text] [Related]
16. OKT3 as prophylaxis immunosuppression in pediatric liver transplant recipients.
Sommerauer JF; Atkison P; Howard J; Grant D; Wall W
Transplant Proc; 1994 Feb; 26(1):154-6. PubMed ID: 8108917
[No Abstract] [Full Text] [Related]
17. Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1993 Aug; 25(4):2574. PubMed ID: 8356675
[No Abstract] [Full Text] [Related]
18. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
[TBL] [Abstract][Full Text] [Related]
19. Spurious elevation of serum thyrotropin (TSH) after OKT3 administration.
Goffin E; Lambert M; De Nayer P; Saint-Remy JM; Pirson Y; van Ypersele de Strihou C
Nephrol Dial Transplant; 1994; 9(10):1500-2. PubMed ID: 7816271
[No Abstract] [Full Text] [Related]
20. Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients.
Niaudet P; Jean G; Broyer M; Chatenoud L
Pediatr Nephrol; 1993 Jun; 7(3):263-7. PubMed ID: 8518095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
